• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于估计I期临床试验中最大耐受剂量的贝叶斯优化方法。

Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials.

作者信息

Takahashi Ami, Suzuki Taiji

机构信息

Department of Mathematical and Computing Science, School of Computing, Tokyo Institute of Technology, Tokyo, Japan.

Biometrics and Data Management, Clinical Statistics, Pfizer R&D Japan, Tokyo, Japan.

出版信息

Contemp Clin Trials Commun. 2021 Feb 15;21:100753. doi: 10.1016/j.conctc.2021.100753. eCollection 2021 Mar.

DOI:10.1016/j.conctc.2021.100753
PMID:33681528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910500/
Abstract

We introduce a Bayesian optimization method for estimating the maximum tolerated dose in this article. A number of parametric model-based methods have been proposed to estimate the maximum tolerated dose; however, parametric model-based methods need an assumption that dose-toxicity relationships follow specific theoretical models. This assumption potentially leads to suboptimal dose selections if the dose-toxicity curve is misspecified. Our proposed method is based on a Bayesian optimization framework for finding a global optimizer of unknown functions that are expensive to evaluate while using very few function evaluations. It models dose-toxicity relationships with a nonparametric model; therefore, a more flexible estimation can be realized compared with existing parametric model-based methods. Also, most existing methods rely on point estimates of dose-toxicity curves in their dose selections. In contrast, our proposed method exploits a probabilistic model for an unknown function to determine the next dose candidate without ignoring the uncertainty of posterior while imposing some dose-escalation limitations. We investigate the operating characteristics of our proposed method by comparing them with those of the Bayesian-based continual reassessment method and two different nonparametric methods. Simulation results suggest that our proposed method works successfully in terms of selections of the maximum tolerated dose correctly and safe dose allocations.

摘要

在本文中,我们介绍一种用于估计最大耐受剂量的贝叶斯优化方法。已经提出了许多基于参数模型的方法来估计最大耐受剂量;然而,基于参数模型的方法需要一个假设,即剂量-毒性关系遵循特定的理论模型。如果剂量-毒性曲线指定错误,这个假设可能会导致次优的剂量选择。我们提出的方法基于一个贝叶斯优化框架,用于找到未知函数的全局优化器,这些函数评估成本高昂,同时仅使用极少的函数评估。它使用非参数模型对剂量-毒性关系进行建模;因此,与现有的基于参数模型的方法相比,可以实现更灵活的估计。此外,大多数现有方法在剂量选择时依赖于剂量-毒性曲线的点估计。相比之下,我们提出的方法利用未知函数的概率模型来确定下一个剂量候选,在施加一些剂量递增限制的同时不忽略后验的不确定性。我们通过将我们提出的方法与基于贝叶斯的连续重新评估方法以及两种不同的非参数方法进行比较,来研究其操作特性。模拟结果表明,我们提出的方法在正确选择最大耐受剂量和安全剂量分配方面成功有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d14/7910500/fc55008baf8f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d14/7910500/fc55008baf8f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d14/7910500/fc55008baf8f/gr1.jpg

相似文献

1
Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials.用于估计I期临床试验中最大耐受剂量的贝叶斯优化方法。
Contemp Clin Trials Commun. 2021 Feb 15;21:100753. doi: 10.1016/j.conctc.2021.100753. eCollection 2021 Mar.
2
Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.贝叶斯优化设计在 I 期临床试验中寻找最大耐受剂量组合。
Int J Biostat. 2021 Apr 5;18(1):39-56. doi: 10.1515/ijb-2020-0147.
3
A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.在单药剂量探索研究中的非参数贝叶斯连续再评估方法。
BMC Med Res Methodol. 2018 Dec 18;18(1):172. doi: 10.1186/s12874-018-0604-9.
4
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.违反单调假设的临床试验中 I 期剂量发现设计的比较。
Clin Trials. 2020 Oct;17(5):522-534. doi: 10.1177/1740774520932130. Epub 2020 Jul 7.
5
Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.基于I/II期临床试验中毒性和疗效结果的剂量探索的贝叶斯优化设计。
Pharm Stat. 2021 May;20(3):422-439. doi: 10.1002/pst.2085. Epub 2020 Nov 30.
6
Shift models for dose-finding in partially ordered groups.部分有序组中剂量探索的转换模型。
Clin Trials. 2019 Feb;16(1):32-40. doi: 10.1177/1740774518801599. Epub 2018 Oct 11.
7
A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.比较Ⅰ期癌症试验中连续评估方法的模型选择。
Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682.
8
Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.建模细胞毒剂 I 期临床试验中不良事件计数。
Clin Trials. 2018 Aug;15(4):386-397. doi: 10.1177/1740774518772309. Epub 2018 May 19.
9
Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.在早期癌症I期试验中使用条件连续重新评估法进行联合用药的剂量探索
J Biom Biostat. 2017;8(6). doi: 10.4172/2155-6180.1000381. Epub 2017 Nov 27.
10
A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.一种用于癌症I期试验的贝叶斯自适应设计,采用灵活的剂量范围。
J Biopharm Stat. 2018;28(3):562-574. doi: 10.1080/10543406.2017.1372774. Epub 2017 Oct 6.

引用本文的文献

1
N-of-1 medicine.N-of-1 医学。
Singapore Med J. 2024 Mar 1;65(3):167-175. doi: 10.4103/singaporemedj.SMJ-2023-243. Epub 2024 Mar 26.
2
The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design.相关β剂量优化方法:使用数学建模和适应性试验设计的最佳疫苗剂量确定
Vaccines (Basel). 2022 Oct 30;10(11):1838. doi: 10.3390/vaccines10111838.

本文引用的文献

1
Evaluating the effects of design parameters on the performances of phase I trial designs.评估设计参数对I期试验设计性能的影响。
Contemp Clin Trials Commun. 2019 May 17;15:100379. doi: 10.1016/j.conctc.2019.100379. eCollection 2019 Sep.
2
A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.在单药剂量探索研究中的非参数贝叶斯连续再评估方法。
BMC Med Res Methodol. 2018 Dec 18;18(1):172. doi: 10.1186/s12874-018-0604-9.
3
Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
多种I期肿瘤学设计的统计操作特征的系统比较。
Contemp Clin Trials Commun. 2016 Nov 24;5:34-48. doi: 10.1016/j.conctc.2016.11.006. eCollection 2017 Mar.
4
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.新型 I 期临床试验设计的准确性、安全性和可靠性。
Clin Cancer Res. 2018 Sep 15;24(18):4357-4364. doi: 10.1158/1078-0432.CCR-18-0168. Epub 2018 Apr 16.
5
Embracing model-based designs for dose-finding trials.采用基于模型的设计进行剂量探索试验。
Br J Cancer. 2017 Jul 25;117(3):332-339. doi: 10.1038/bjc.2017.186. Epub 2017 Jun 29.
6
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.一种解决奥卡姆剃刀问题的贝叶斯区间剂量探索设计:mTPI-2。
Contemp Clin Trials. 2017 Jul;58:23-33. doi: 10.1016/j.cct.2017.04.006. Epub 2017 Apr 27.
7
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.肿瘤学剂量递增临床试验的连续重新评估方法:使用AZD3514数据对先前框架方法的比较
BMC Cancer. 2016 Aug 31;16(1):703. doi: 10.1186/s12885-016-2702-6.
8
Performance of toxicity probability interval based designs in contrast to the continual reassessment method.基于毒性概率区间的设计与连续重新评估方法的性能对比。
Stat Med. 2017 Jan 30;36(2):291-300. doi: 10.1002/sim.7043. Epub 2016 Jul 19.
9
A statistical evaluation of dose expansion cohorts in phase I clinical trials.I期临床试验中剂量扩展队列的统计学评估。
J Natl Cancer Inst. 2015 Feb 20;107(3). doi: 10.1093/jnci/dju429. Print 2015 Mar.
10
Adaptive dose-finding studies: a review of model-guided phase I clinical trials.适应性剂量探索研究:模型引导的I期临床试验综述
J Clin Oncol. 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30.